Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses

Gynecologic Oncology

Volumn 60, Issue 2, 1996, Pages 197-202

  Gadducci, Angiolo ^a   Baicchi, Ugo ^b   Marrai, Roberto ^a   Ferdeghini, Marco ^a   Bianchi, Romano ^a   Facchini, Virgilio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DIMER;

ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 0030028943     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0025     Document Type: Article

References (29)

1. Herrmann, U. J., Jr., Locher, G. W., and Goldhirsch, A. Sonographic patterns of ovarian tumors: Prediction of malignancy, Obstet. Gynecol. 69, 777-781 (1987).
2. Finkler, N. J., Benacerraf, B., Lavin, P. T., Wojciechowski, C., and Knapp, R. C. Comparison of serum CA 125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses, Obstet. Gynecol. 72, 659-664 (1988).
3. Granberg, S., Wikland, M., and Jansson, I. Macroscopic characterization of ovarian tumors and the relation to histological diagnosis: Criteria to be used for ultrasound evaluation, Gynecol. Oncol. 35, 139-144 (1989).
4. Campbell, S., Bhan, V., Royston, P., Whitehead, M. I., and Collins, W. P. Transabdominal ultrasound screening for early ovarian cancer, Br. J. Med. 299, 1363-1367 (1989).
5. Gadducci, A., Capriello, P., Ferdeghini, M., Madrigali, A., Puccetti, A., Annichiarico, C., Prontera, C., Bianchi, R., and Fioretti, P. Pelvic ultrasound, serum CA 125 assay, CA 19.9 assay and serum CA 72.4 assay in the differential diagnosis of ovarian masses, Cancer J. 4, 249-253 (1991).
6. Sassone, A. M., Timor-Tritsch, F., Artner, A., Westhoff, C., and Warren, W. B. Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy, Obstet. Gynecol. 78, 70-76 (1991).
7. Maggino, T., Gadducci, A., D'Addario, V., Pecorelli, S., Lissoni, A., Stella, M., Romagnolo, C., Ferdeghini, M., Zucca, S., Trio, D., and Trovo, S. Prospective multicenter study on CA 125 in postmenopausal pelvic masses, Gynecol. Oncol. 54, 117-123 (1994).
8. O'Connel, G. J., Ryan, E., Murphy, K. J., and Prefontaine, M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses, Obstet. Gynecol. 70, 930-932 (1987).
9. Einhorn, N., Bast, R. C., Jr., Knapp, R. C., Tjernberg, B., and Zurawski, V. R., Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer, Obstet. Gynecol. 67, 414-416 (1986).
10. Malkasian, G. D., Jr., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Jr., Podratz, K. C., Stanhope, R., Mortel, R., Berek, J. S., Bast, R. C., Jr., and Ritts, R. E. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease, Am. J. Obstet. Gynecol. 159, 341-346 (1988).
11. Vasilev, S. A., Schlaerth, J. B., Campeau, J., and Morrow, C. P. Serum CA 125 levels in preoperative evaluation of pelvic masses, Obstet. Gynecol. 71, 751-756 (1988).
12. Jacobs, I., and Bast, R. C., Jr. The CA 125 tumour-associated antigen: A review of the literature, Hum. Reprod. 4, 1-12 (1989).
13. Gadducci, A., Ferdeghini, M., Prontera, C., Moretti, L., Mariani, G., Bianchi, R., and Fioretti, P. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis, Gynecol. Oncol. 44, 147-154 (1992).
14. Rickles, F. R., and Edwards, R. L. Activation of blood coagulation in cancer: Trousseau's Syndrome revisited, Blood 62, 14-31 (1983).
15. Nand, S. Hemostasis and cancer, Cancer J. 6, 54-58 (1993).
16. Nagy, J. A., Brown, L. F., Senger, D. R., Lanir, N., Van De Water, L., Dvorak, A. M., and Dvorak, H. F. Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition, Biochim. Biophys. Acta 948, 305-326 (1988).
17. Olander, J. V., Bremer, M. E., Marase, J. C., and Feder, J. Fibrin enhanced endothelial cell organization, J. Cell. Physiol. 125, 1-9 (1985).
18. Zacharski, L. R., Costantini, V., Wojtukiewicz, M. Z., Memoli, V. A., and Kudryk, B. J. Anticoagulants as cancer therapy, Semin. Oncol. 17, 217-227 (1990).
19. Rylatt, D. B., Blake, A. S., Cottes, L. E., Massingam, D. A., Fletcher, W. A., Masci, P. P., Whitaker, A. N., Elms, M., Bunce, I., Webber, A. J., Wyatt, D., and Bundensen, P. G. An immunoassay for human D-dimer using monoclonal antibodies, Thromb. Res. 31, 767-778 (1983).
20. Bick, R. L. Coagulation abnormalities in malignancy: A review, Semin. Thromb. Hemost. 18, 353-372 (1992).
21. Mirshahi, S. S., Pujade-Lauraine, E., Soria, C., Mirshahi, M., Fretault, J., Bernadou, A., and Soria, J. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy: Prognostic significance for the success of anticancer treatment, Cancer 69, 2289-2292 (1992).
22. Gadducci, A., Baicchi, U., Marrai, R., Del Bravo, B., Fosella, P. V., and Facchini, V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma, Gynecol. Oncol. 53, 352-356 (1994).
23. Wojtukiewicz, M. Z., Zacharski, L. R., Moritz, T. E., Hur, K., Edwards, R. L., and Rickles, F. R. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon, Blood Coagulation Fibrinolysis 3, 429-437 (1992).
24. Zacharski, L. R., Wojtukiewicz, M. Z., Costantini, V., Ornstein, D. L., and Memoli, V. A. Pathways of coagulation/fibrinolysis activation in malignancy, Semin. Thromb. Hemostasis 18, 104-116 (1992).
25. Zacharski, L. R., Memoli, V. A., Ornstein, D. L., Rousseau, S. M., Kisiel, W., and Kudryk, B. J. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary, J. Natl. Cancer Inst. 85, 1225-1230 (1993).
26. Sagripanti, A., Carpi, A., Ferdeghini, M., Baicchi, U., and Grassi, B. Plasmatic markers of haemostatic system activation in patients with solid neoplasms, J. Nucl. Med. Allied Sci. 34, 321-332 (1990).
27. Hafter, R., Schrock, R., Von Hugo, R., and Graeff, H. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and Latex test, Scand. J. Clin. Lab. Invest. 45, 137-144 (1985).
28. Schrock, R., Hafter, R., Graeff, H., and Schmid, L. Die simultane bestimmung von CA 125 und D-dimer in plasma and aszites beim ovarialkarzinom, Gakologie 8, 260-262 (1985).
29. Khoo, S. K., Rylatt, D. B., Parsons, P., Wilson, K., Webb, M. J., Dickie, G., Kearsley, J., and Mackay, E. V. Serial D-dimer levels in the assessment of tumor mass and clinical outcome in ovarian cancer, Gynecol. Oncol. 29, 188-198 (1988).